Clinical trial data has shown that dual blockade of the RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent.
Tell the doctor or pharmacist if the patient is taking, has recently taken or might take any other medicines.
The doctor may need to change the dose and/or to take other precautions: If the patient is taking an ACE-inhibitor or aliskiren (see also information under Contraindications and Precautions).
The patient may need to have blood checks if taking: potassium supplements, salt substitutes containing potassium, potassium-sparing medicines (such as certain diuretics), medicines containing lithium.
If the patient is taking certain painkillers, called non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.
Irbegen with food and drink: Irbegen can be taken with or without food.